The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation.
Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives.
Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.
“As an ambitious organization, we knew we needed a leader with a breadth of experience who can push us to the next level,” says Patti Pearce, The Max Foundation CFO and VP of Administration. “I have total confidence in Wilma’s leadership and experience to drive success.”
Wilma will join The Max Foundation’s Seattle headquarters office and oversee The Max Foundation’s development and communication departments.
“I am honored to have the opportunity to join The Max Foundation,” says Wilma. “I’ve been impressed with the organization from the start and feel connected to the mission of providing dignity and hope to cancer patients worldwide.”
Please join us in welcoming Wilma Comenat as The Max Foundation’s Vice President of Development.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
On the sidelines of UNGA80, global health leaders explored ways to expand access to care and build resilient health systems, and the critical role partnerships play in ensuring sustainable impact. Read More
The Max Foundation to launch its Max Access Solutions program for patients with HR+/HER2- advanced breast cancer in collaboration with leading oncologists in low- and middle-income countries (LMICs) and the ABC Global Alliance, the American Society for Clinical Pathology, Cepheid, and Novartis AG First patients to receive treatment in Bahamas, Benin, Bhutan, Haiti, Jamaica, Mozambique,….
Agreement to provide Verzenio® (abemaciclib) free of charge to patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) Lilly joins ongoing effort of Humanitarian Partnership for Access to Critical Treatment (Humanitarian PACT) to eliminate healthcare disparities for patients living with advanced breast cancer in low- and middle-income countries….
